The number of people diagnosed with asbestos caused diseases in the U.S. continues to increase. Experts believe 60,000 mesothelioma deaths will occur between 2010 and 2030.

Work related injuries harm up to 14 million people annually, with harms including traumatic brain injuries, spinal injuries, amputations, burns, and electrocutions. Around 20,000 to 60,000 workers die each year from accidents, toxins, and violence at their jobs.

Millions of consumers and workers are injured each year because of defective products. Defects can occur when a product is designed poorly, when a product is manufactured in a manner that differs from the intended design, or when the product does not contain proper warnings or instructions. Defects can occur in automobiles, pharmaceuticals, medical devices, construction equipment, toys, and other goods.

Between 1.5 and 2 million elderly reside in nursing home facilities, with studies revealing that 44% have suffered some form of abuse. Many believe the actual number of residents suffering abuse is much higher. Neglect and abuse may result in serious emotional, physical, and financial harm

Paul & Hanley’s legal team has produced some of the most notable verdicts and highest settlements in the United States. Over 500 of our clients have each obtained in excess of 1 million dollars. Over 250 have recovered multi-million dollar recoveries.

Staging System for Malignant Mesothelioma

The following is a technical discussion of staging for malignant mesothelioma written for health professionals.

The American Joint Committee on Cancer (AJCC) staging system for mesothelioma was adopted from that proposed by the IMIG in 1995 and has been validated in a number of surgically based trials.  The system evolved from a greater understanding of the relationships between the tumor (T) status and nodal (N) status and overall survival.  There was a redefinition of the T categories, and the T1 lesions were divided into T1a (involvement of the parietal pleura only) and T1b (involvement of the visceral pleura), which led to a split of stage I into state IA and IB.  T3 is defined as a locally advanced but potentially resectable tumor, and T4 is defined as a locally advanced, technically unresectable tumor.  The Brigham and Woman’s Staging System has also been proposed for pleural mesothelioma and differs from the AJCC by defining intrapleural adenopathy (lymph node involvement near the pleura) as stage II disease and extrapleural adenopathy as stage III disease.  The AJCC system classifies any nodal involvement, either intrapleural or extrapleural as stage III disease.

International Staging System for Diffuse Malignant Pleural Mesothelioma

T-TUMOR STATUS

T1

T1a

Tumor limited to the ipsilateral parietal ± mediastinal ± diaphragmatic pleura

No involvement of the visceral pleura

T1b

Tumor involving the ipsilateral parietal ± mediastinal ± diaphragmatic pleura

Tumor also involving the visceral pleura

T2

Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features:

Involvement of diaphragmatic muscle

Extension of tumor from visceral pleura into the underlying pulmonary parenchyma

T3

Describes locally advanced but potentially respectable tumor

Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features:

Involvement of the endothoracic fascia

Extension into the mediastinal fat

Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall.

Nontransmural involvement of the pericardium

T4

Describes locally advanced technically unresectable tumor

Tumor involving all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features:

Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction

Direct transdiaphragmatic extension of tumor to the peritoneum

Direct extension of tumor to the contralateral pleura

Direct extension of tumor to mediastinal organs

Direct extension of tumor into the spine

Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium

 

N-LYMPH NODES

NX: Regional lymph nodes cannot be assessed

N0: No regional lymph node metastases

N1: Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes

N2: Metastases in the subcarinal or the ipsilateral mediastinal lymph noes, including the ipsilateral internal mammary nodes

N3: Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral, or contralateral supraclavicular lymph nodes

M-METASTASES

MX: Presence of distant metastases cannot be assessed

M0: No distant metastasis

M1: Distant metastasis present

 

STAGE

STAGE I

Ia: T1aN0 M0

Ib: T1bN0 M0

STAGE II

T2 N0 M0

STAGE III

Any T3 M0

Any N1 M0

Any N2 M0

STAGE IV

Any T4

Any N3

Any M1

Paul & Hanley LLP has an outstanding track record of success, and our lawyers are known for their honesty, integrity and compassion.  If you or a loved one has been diagnosed with Mesothelioma or any asbestos related disease from asbestos exposure we can help you file a Mesothelioma lawsuit. We also handle car injury cases, wrongful death cases, product defect cases, premises liability cases, and work related injury cases. Our experienced legal team is here to help you get just financial compensation for your injuries.



    * More than 25 years of experience in Mesothelioma and Asbestos litigation.

    * More than 1 billion dollars in settlements.

    * Over 500 of our clients have recovered in excess of 1 million dollars.



Call us today at 800.281.9804 for a free and confidential consultation with an experienced Mesothelioma Lawyer.